Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viventia's Cancer Ambitions Go To Eleven

Executive Summary

Merger with troubled ophthalmology biotech Eleven takes Viventia public and joins the protein-engineering and manufacturing expertise of the two firms. Lead candidate Vicinium is in Phase III for high-grade, non-muscle invasive bladder cancer.

You may also be interested in...



Report: Women Eschew Life Science Companies That Lack Female Leadership

MassBio and Liftstream partnered on a report about women's, men's and companies' views on gender diversity in the life science industry and identified several opportunities for employers to improve, including the need to employ more women in leadership roles to attract female job-seekers.

J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?

Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.

J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value

Plunging biopharma company stock values and declining IPO activity have contributed to a more difficult financing environment, but money is still available for public and private drug developers whose products provide value in the eyes of patients and payers.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC097340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel